Aylin Ulku • UCSF Profiles

Aylin Ulku, MD, PhD

Title(s)	Associate Professor, Medicine
School	School of Medicine
Phone	--
vCard	Download vCard

Biography

Education and Training

UNC Chapel Hill, Chapel Hill, NC	MD PhD	06/2005	MD, PhD in Pharmacology
Yalen New Haven Hospital, New Haven, CT		06/2009	Combined Medicine-Pediatric Residency
University of California, San Francisco, CA		2018	Diversity, Equity, and Inclusion Champion Training

Awards and Honors

Yale-New Haven Hospital

2010

Hugh Dwyer Award for Clincal Excellence

Overview

Aylin Ulku joined the faculty at UCSF in July 2012 as an Assistant Clinical Professor in the Division of Hospital Medicine. After completing her Combined Internal Medicine-Pediatrics Residency at Yale-New Haven Hospital, she continued as Chief Resident in the Primary Care Internal Medicine Residency at Waterbury/Yale-New Haven Hospitals. In 2010, she began work in Kigali, Rwanda, as an Assistant Clinical Professor for Yale School of Medicine, to assist in medical education capacity building within the National University of Rwanda (NUR) School of Medicine. Her work included direct teaching and clinical care supervising Rwandese medical students and residents in Internal Medicine and Pediatrics as well as collaboration with NUR and the Rwanda Ministry of Health in revising undergraduate and graduate curricula and training programs. Her clinical and research interests focus on global health education and training in non-communicable diseases in limited-resource settings.

Education:
- Princeton University, Chemistry (BA)
- University of North Carolina, Chapel Hill (MD-PhD - pharmacology)
- Yale-New Haven Hospital (intership, residency, chief resident)

Board Certifications:
- Internal Medicine (2010)
- Pediatrics (2010)

Interests

global health education, medical education, equal access to healthcare, care transition

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.

Altmetrics Details

PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.

Genetic and pharmacologic dissection of Ras effector utilization in oncogenesis. Methods Enzymol. 2006; 407:195-217. Campbell PM, Singh A, Williams FJ, Frantz K, Ulkü AS, Kelley GG, Der CJ. PMID: 16757325.

View in: PubMed Mentions: 8 Fields:
Bio Biochemistry
Translation:Humans Cells
Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem. 2005 Jun 17; 280(24):23363-70. Pruitt K, Ulkü AS, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, Der CJ, Shields JM. PMID: 15831492.

View in: PubMed Mentions: 31 Fields:
Bio Biochemistry
Translation:Humans Animals Cells
Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int J Cancer. 2004 Nov 01; 112(2):190-9. Collette J, Ulku AS, Der CJ, Jones A, Erickson AH. PMID: 15352030.

View in: PubMed Mentions: 9 Fields:
Neo Neoplasms
Translation:Animals Cells
Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res. 2004 Jul 01; 64(13):4585-92. Eckert LB, Repasky GA, Ulkü AS, McFall A, Zhou H, Sartor CI, Der CJ. PMID: 15231670.

View in: PubMed Mentions: 102 Fields:
Neo Neoplasms
Translation:Humans Cells
Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. Mol Cancer Res. 2003 Dec; 1(14):1077-88. Ulkü AS, Schäfer R, Der CJ. PMID: 14707291.

View in: PubMed Mentions: 4 Fields:
Cel Cell Biology Mol Molecular Biology Neo Neoplasms
Translation:Animals Cells
RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem. 2003 Jul 25; 278(30):28045-51. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. PMID: 12732644.

View in: PubMed Mentions: 72 Fields:
Bio Biochemistry
Translation:Humans Animals Cells
Ras signaling, deregulation of gene expression and oncogenesis. Cancer Treat Res. 2003; 115:189-208. Ulkü AS, Der CJ. PMID: 12613198.

View in: PubMed Mentions: 14 Fields:
Neo Neoplasms The Therapeutics
Translation:Humans Animals Cells
Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function. Methods Enzymol. 2001; 332:3-36. Fiordalisi JJ, Johnson RL, Ulkü AS, Der CJ, Cox AD. PMID: 11305105.

View in: PubMed Mentions: 21 Fields:
Bio Biochemistry
Translation:Humans Animals Cells